Evotec AG, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brendan Smith from TD Cowen maintained a Buy rating on the stock and has a $7.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Brendan Smith’s rating is based on a combination of factors that suggest potential long-term growth for Evotec AG. Despite the company’s recent revenue shortfall due to challenges in the Discovery & Preclinical Development segment, there is notable growth in the Just-Evotec Biologics division, which has expanded its customer base and increased revenues by 23% year-over-year. This growth momentum in JEB is seen as a positive counterbalance to the weaknesses in other areas.
Additionally, the upcoming sale of the Toulouse manufacturing facility to Sandoz for over $300 million is expected to strengthen Evotec’s financial position. This transaction not only provides immediate capital but also offers future revenue opportunities through development revenues, milestones, and royalties. The company’s new ‘Restart’ strategy, focusing on capital-efficient models and next-generation innovation, is anticipated to drive long-term growth in high-value sectors, further supporting the Buy rating.